Navigation Links
CSHL scientists trace causal link between a tumor suppressor gene and liver cancer
Date:6/3/2008

Scientists at Cold Spring Harbor Laboratory (CSHL) have taken the search for cancer-causing genes an important step forward. In a newly published paper, they confirm that a gene called DLC1 is a tumor suppressor. They have demonstrated in living mice that its deletion, inactivation or loss precipitates events culminating in an aggressive type of liver cancer closely related to common human epithelial cancers of the liver (also known as hepatocellular carcinoma, or HCC).

The team's success in tracing the intricate pathway by which DLC1 functions in both healthy and pathological states suggests a highly specific new target for future anticancer drugs.

Focusing on a Suspected Tumor Suppressor Tumor suppressor genes play a vital role in intracellular signaling networks that protect against uncontrolled cell growth and proliferation. Such genes can be rendered inactive by a variety of DNA alterations, including deletions, mutations and so-called epigenetic changes in DNA's chemical configuration. DLC1 a gene whose acronym reflects prior suspicions that it was "deleted in liver cancer" was known to be located in a region of chromosome 8 that has been observed to be missing in past studies of mammalian liver cancer cells. "The region in question is a large one that may harbor more than one tumor suppressor," said Dr. Scott W. Lowe. "We set out to conclusively identify DLC1 as a tumor suppressor, which had not been done before, and to show at the molecular level how the absence of this gene produces pathology in cells that can lead to liver cancer. Interestingly, loss of DLC1 is observed in a range of epithelial cancers, which suggests that DLC1 may a play common role in many types of human cancer."

In addition to corresponding author Lowe, the research team included five other laboratory heads at CSHL: Prof. Linda Van Aelst, Ph.D., and Prof. Michael Wigler, Ph.D.; Assoc. Prof. Scott Powers, Ph.D.; and Asst. Prof. Robert Lucito, Ph.D., and

Asst. Prof. Raffaella Sordella, Ph.D.; as well as Lars Zender, M.D., professor at the Helmholtz Center, Germany. Their collaborative paper, whose lead authors are Wen Xue, Ph.D., of the Lowe lab, and Alexander Krasnitz, Ph.D., of the Wigler lab, appears in the June 1 issue of Genes & Development.

Connecting the Gene to Liver Cancers

To prove that DLC1 was causally implicated in specific cancers, the team genetically engineered mouse liver cells in which the gene was not expressed. Short-hairpin RNAs (shRNAs) were designed to "knock down" DLC1 expression in vivo. When the DLC1 shRNAs are introduced into normal mouse liver cells, the production of DLC1 protein is blocked, or 'silenced.' The team observed that nearly all of the mice whose livers had been transplanted with the engineered cells developed liver cancer, and that the gene's reintroduction stopped the cancer. However, this was only the beginning of the experimental road, for it is not simply the absence of the DLC1 protein that causes tumorigenesis. In fact, abnormally low levels of the protein, or its complete absence, induces a complex series of interrelated events, as Dr. Lowe and colleagues demonstrated. The protein encoded by the DLC1 gene belongs to regulators of a large family of enzymes called small Rho GTPases that act as molecular switches.

Following the Signaling Pathway Using a mechanism called RNA interference to control the expression of specific genes, the team effectively turned the DLC1 "switch" on and off in living mice cells, and in so doing was able to isolate one particular signaling intermediary whose presence was both necessary and sufficient to set the cell on an uncontrolled growth path. This essential molecular intermediary is called RhoA. When the DLC1 gene is absent in a cell, RhoA is activated, effectively removing a brake on tumor initiation. Whether the experimenters knocked down the DLC1 gene or in separate experiments activated RhoA, the result was the same: the promotion of liver cancer.

Specifically, the team demonstrated that RhoA is required for maintaining the tumor-formation process stimulated by deletion of the DLC1 gene.

"This suggests an opportunity for molecularly targeted therapies," Dr. Lowe said. "For a variety of reasons, tumor suppressors like DLC1 are not amenable to direct therapeutic targeting. But we may be able to readily target cancer-promoting molecules like RhoA that are 'downstream' in the signaling cascade.

"Our data show that RhoA is required for maintenance of at least some tumors driven by DLC1 loss, and also that cells with disabled DLC1 are particularly sensitive to inhibitors that target at least one of the molecular 'effectors' that renders RhoA active. We know that DLC1 is frequently lost in human epithelial cancers. This suggests that drug intervention in the signaling pathways modulated by DLC1 may have broad therapeutic utility."

"DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma" appears in Genes & Development on June 1. The complete citation is: Wen Xue, Alexander Krasnitz, Robert Lucito, Raffaella Sordella, Linda Van Aelst, Carlos Cordon-Cardo, Stephan Singer, Florian Kuehnel, Michael Wigler, Scott Powers, Lars Zender, and Scott W. Lowe. The paper is available online at: http://www.genesdev.org/cgi/content/full/22/11/1439


'/>"/>

Contact: Jim Bono
bono@cshl.edu
516-367-8455
Cold Spring Harbor Laboratory
Source:Eurekalert

Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Scientists Probe Sepsis Deadly Secrets
3. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
4. Scientists Develop Natural Protection for Stored Foods
5. Scientists detect presence of marburg virus in african fruit bats
6. Scientists Spot Brains Free Will Center
7. Scientists ID Likely Culprit in Popcorn Lung
8. Scientists explain how insulin secreting cells maintain their glucose sensitivity
9. Scripps Research scientists shed new light on how antibodies fight HIV
10. Scientists, physicians present latest findings in personalized cancer treatment and prevention
11. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a ... centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... -- AVACEN Medical , Inc. (AVACEN) announced that Frost ... Product Innovation Award for Its fibromyalgia pain management device. ... device market research by Frost & Sullivan,s industry experts. ... relief product, the AVACEN 100, offers a safe and effective ... ...
(Date:10/12/2017)... -- West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today announced that it will release third-quarter 2017 ... 26, 2017, and will follow with a conference call ... a.m. Eastern Time. To participate on the call, please ... is 94093362. A ...
(Date:10/11/2017)...  Caris Life Sciences ® , a leading innovator ... precision medicine, today announced that St. Jude Medical Center,s ... (POA) as its 17 th member. Through participation ... Cancer Institute will help develop standards of care and ... making cancer treatment more precise and effective. ...
Breaking Medicine Technology: